StemCell Therapy

Vir Biotechnology Inc. (NASDAQ:VIR) went down by -9.01% from its latest closing price compared to the recent 1-year high of $75.00. The companys stock price has collected 2.69% of gains in the last five trading sessions. Press Release reported on 09/24/20 that Vir Biotechnology Publishes New Research Characterizing Antibody Response to SARS-CoV-2 in the Journal Cell

Opinions of the stock are interesting as 4 analysts out of 7 who provided ratings for Vir Biotechnology Inc. declared the stock was a buy, while 0 rated the stock as overweight, 2 rated it as hold, and 0 as sell.

The average price from analysts is $50.67, which is $17.34 above the current price. VIR currently public float of 109.06M and currently shorts hold a 4.67% ratio of that float. Today, the average trading volume of VIR was 1.18M shares.

VIR stocks went up by 2.69% for the week, with a monthly drop of -15.19% and a quarterly performance of -13.31%. The volatility ratio for the week stands at 9.00% while the volatility levels for the past 30 days are set at 10.19% for Vir Biotechnology Inc.. The simple moving average for the period of the last 20 days is 6.75% for VIR stocks with a simple moving average of 3.21% for the last 200 days.

Many brokerage firms have already submitted their reports for VIR stocks, with Goldman repeating the rating for VIR by listing it as a Buy. The predicted price for VIR in the upcoming period, according to Goldman is $54 based on the research report published on September 14th of the current year 2020.

JP Morgan, on the other hand, stated in their research note that they expect to see VIR reach a price target of $29. The rating they have provided for VIR stocks is Neutral according to the report published on September 11th, 2020.

Needham gave a rating of Buy to VIR, setting the target price at $62 in the report published on August 20th of the current year.

After a stumble in the market that brought VIR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.23% of loss for the given period.

Volatility was left at 10.19%, however, over the last 30 days, the volatility rate increased by 9.00%, as shares surge +1.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -34.16% lower at present.

During the last 5 trading sessions, VIR rose by +2.69%, which changed the moving average for the period of 200-days by +151.32% in comparison to the 20-day moving average, which settled at $32.18. In addition, Vir Biotechnology Inc. saw 173.00% in overturn over a single year, with a tendency to cut further gains.

Reports are indicating that there were more than several insider trading activities at VIR starting from Virgin Herbert, who sale 3,805 shares at the price of $31.71 back on Sep 22. After this action, Virgin Herbert now owns 20,000 shares of Vir Biotechnology Inc., valued at $120,638 using the latest closing price.

Pang Phillip, the Chief Medical Officer of Vir Biotechnology Inc., sale 12,500 shares at $31.90 during a trade that took place back on Sep 16, which means that Pang Phillip is holding 29,777 shares at $398,694 based on the most recent closing price.

Current profitability levels for the company are sitting at:

The net margin for Vir Biotechnology Inc. stands at -2158.98. The total capital return value is set at -62.52, while invested capital returns managed to touch -62.97. Equity return is now at value -81.10, with -42.30 for asset returns.

Based on Vir Biotechnology Inc. (VIR), the companys capital structure generated 0.27 points at debt to equity in total, while total debt to capital is 0.27. Total debt to assets is 0.22, with long-term debt to equity ratio resting at 0.21. Finally, the long-term debt to capital ratio is 0.21.

When we switch over and look at the enterrpise to sales, we see a ratio of 119.29, with the companys debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 6.81.

Read more:
We Analyzed the Future Direction of Vir Biotechnology Inc. (VIR), Here is What We Found - The News Heater

A rating of 34 puts Abeona Therapeutics Inc (ABEO) near the middle of the Biotechnology industry according to InvestorsObserver. Abeona Therapeutics Inc's score of 34 means it scores higher than 34% of stocks in the industry. Abeona Therapeutics Inc also received an overall rating of 40, putting it above 40% of all stocks. Biotechnology is ranked 27 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Abeona Therapeutics Inc (ABEO) stock is unmoved -0.48% while the S&P 500 is lower by -1.28% as of 11:06 AM on Friday, Oct 2. ABEO is flat $0.00 from the previous closing price of $1.05 on volume of 1,099,195 shares. Over the past year the S&P 500 has gained 14.67% while ABEO is lower by -53.54%. ABEO lost -$1.31 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Abeona Therapeutics Inc (ABEO) Stock.

Excerpt from:
Is Abeona Therapeutics Inc (ABEO) The Right Choice in Biotechnology? - InvestorsObserver

Vaxart Inc (VXRT) is around the top of the Biotechnology industry according to InvestorsObserver. VXRT received an overall rating of 81, which means that it scores higher than 81 percent of all stocks. Vaxart Inc also achieved a score of 93 in the Biotechnology industry, putting it above 93 percent of Biotechnology stocks. Biotechnology is ranked 23 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 81 would rank higher than 81 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Vaxart Inc (VXRT) stock has risen 8.5% while the S&P 500 is lower by -1.67% as of 11:41 AM on Monday, Sep 21. VXRT is up $0.70 from the previous closing price of $8.22 on volume of 23,715,904 shares. Over the past year the S&P 500 has gained 9.10% while VXRT is up 1615.38%. VXRT lost -$0.60 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Vaxart Inc (VXRT) Stock.

Follow this link:
Is Vaxart Inc (VXRT) The Right Choice in Biotechnology? - InvestorsObserver

Chicago, United States: The global Agricultural Biotechnology For Transgenic Crops Market is carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Agricultural Biotechnology For Transgenic Crops Market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Agricultural Biotechnology For Transgenic Crops Market. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Agricultural Biotechnology For Transgenic Crops Market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Agricultural Biotechnology For Transgenic Crops Market.

Leading players of the global Agricultural Biotechnology For Transgenic Crops Market are analyzed taking into account their market share, recent developments, new product launches, partnerships, mergers or acquisitions, and markets served. We also provide an exhaustive analysis of their product portfolios to explore the products and applications they concentrate on when operating in the global Agricultural Biotechnology For Transgenic Crops Market. Furthermore, the report offers two separate market forecasts one for the production side and another for the consumption side of the global Agricultural Biotechnology For Transgenic Crops Market. It also provides useful recommendations for new as well as established players of the global Agricultural Biotechnology For Transgenic Crops Market.

Request for Sample Copy of This Report @https://www.reporthive.com/request_sample/2437198

Major Players:Monsanto, DowDuPont, Syngenta, BayerCropScience, Rubicon, Vilmorin, CertisUSA, Evogene, KWSSAAT, ADAMAAgriculturalSolutions, PerformancePlants, GlobalBio-chemTechnology

Segmentation by Product:

Artificial Genetically Modified (GM)Natural Genetically Modified (GM)

Segmentation by Application:

CornSoybeanCottonOthers

For Customised Template PDF Report:https://www.reporthive.com/request_customization/2437198

Scope of the Report:The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Agricultural Biotechnology For Transgenic Crops Market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

The insight has been added in the report to provide realistic overview of the industry, consist of Agricultural Biotechnology For Transgenic Cropsmanufacturers data, i.e. shipment, price, revenue, gross profit, business distribution, etc., SWOT analysis, consumer preference, recent developments and trends, drivers and restrain factors, company profile, investment opportunity, demand gap analysis, forecast market size value/volume, services and product, Porters Five Models, socioeconomic factors, government regulation in Agricultural Biotechnology For Transgenic Crops industry. Market players can use the report to peep into the future of the global Agricultural Biotechnology For Transgenic Crops Market and bring important changes to their operating style and marketing tactics to achieve sustained growth.

Global Agricultural Biotechnology For Transgenic Crops Market: Competitive RivalryThe chapter on company profiles studies the various companies operating in the global Agricultural Biotechnology For Transgenic Crops Market. It evaluates the financial outlooks of these companies, their research and development statuses, and their expansion strategies for the coming years. Analysts have also provided a detailed list of the strategic initiatives taken by the Agricultural Biotechnology For Transgenic Crops Market participants in the past few years to remain ahead of the competition.

Main Aspects covered in the Report->>Overview of the Agricultural Biotechnology For Transgenic Crops market including production, consumption, status & forecast and market growth->>2016-2020 historical data and 2021-2026 market forecast->>Geographical analysis including major countries->>Overview the product type market including development->>Overview the end-user market including development->>Impact of Coronavirus on the Industry

Table of Contents

Report Overview:It includes major players of the global Agricultural Biotechnology For Transgenic Crops Market covered in the research study, research scope, and Market segments by type, market segments by application, years considered for the research study, and objectives of the report.

Global Growth Trends:This section focuses on industry trends where market drivers and top market trends are shed light upon. It also provides growth rates of key producers operating in the global Agricultural Biotechnology For Transgenic Crops Market. Furthermore, it offers production and capacity analysis where marketing pricing trends, capacity, production, and production value of the global Agricultural Biotechnology For Transgenic Crops Market are discussed.

Market Share by Manufacturers:Here, the report provides details about revenue by manufacturers, production and capacity by manufacturers, price by manufacturers, expansion plans, mergers and acquisitions, and products, market entry dates, distribution, and market areas of key manufacturers.

Market Size by Type:This section concentrates on product type segments where production value market share, price, and production market share by product type are discussed.

Market Size by Application:Besides an overview of the global Agricultural Biotechnology For Transgenic Crops Market by application, it gives a study on the consumption in the global Agricultural Biotechnology For Transgenic Crops Market by application.

Production by Region:Here, the production value growth rate, production growth rate, import and export, and key players of each regional market are provided.

Consumption by Region:This section provides information on the consumption in each regional market studied in the report. The consumption is discussed on the basis of country, application, and product type.

Company Profiles:Almost all leading players of the global Agricultural Biotechnology For Transgenic Crops Market are profiled in this section. The analysts have provided information about their recent developments in the global Agricultural Biotechnology For Transgenic Crops Market, products, revenue, production, business, and company.

Market Forecast by Production:The production and production value forecasts included in this section are for the global Agricultural Biotechnology For Transgenic Crops Market as well as for key regional markets.

Market Forecast by Consumption:The consumption and consumption value forecasts included in this section are for the global Agricultural Biotechnology For Transgenic Crops Market as well as for key regional markets.

Value Chain and Sales Analysis:It deeply analyzes customers, distributors, sales channels, and value chain of the global Agricultural Biotechnology For Transgenic Crops Market.

Key Findings: This section gives a quick look at important findings of the research study.

About Us:Report Hive Research delivers strategic market research reports, statistical surveys, industry analysis and forecast data on products and services, markets and companies. Our clientele ranges mix of global business leaders, government organizations, SMEs, individuals and Start-ups, top management consulting firms, universities, etc. Our library of 700,000 + reports targets high growth emerging markets in the USA, Europe Middle East, Africa, Asia Pacific covering industries like IT, Telecom, Semiconductor, Chemical, Healthcare, Pharmaceutical, Energy and Power, Manufacturing, Automotive and Transportation, Food and Beverages, etc. This large collection of insightful reports assists clients to stay ahead of time and competition. We help in business decision-making on aspects such as market entry strategies, market sizing, market share analysis, sales and revenue, technology trends, competitive analysis, product portfolio, and application analysis, etc.

Contact Us:

Report Hive Research

500, North Michigan Avenue,

Suite 6014,

Chicago, IL 60611,

United States

Website: https://www.reporthive.com

Email: [emailprotected]

Phone: +1 312-604-7084

Read the original post:
Global Covid-19 impact on Agricultural Biotechnology For Transgenic Crops Market: Business Opportunities, Current Trends And Industry Analysis By 2020...

One of the biggest winners among coronavirus stocks in 2020 has been Vir Biotechnology(NASDAQ:VIR). The company's shares have more than doubled in the span of one year, turning a $10,000 investment from last September into about $22,700 today. That substantially outperformed the S&P 500, which gained 15% over the same period.

But sometimes, the higher you climb, the harder you fall. Recent controversy surrounding the company's progress with its COVID-19 programs caused the stock to fall more than 40% from its peak in late August. Should investors expect this company and its stock to rebound? Let's take a look at whether buying Vir on the dip is a golden opportunity or whether the company's drug pipeline spells trouble for its future.

Image Source: Getty Images.

Vir has two antibody treatments and a small interfering RNA (siRNA) treatment against COVID-19 in its pipeline. siRNA therapeutic candidates are based on tiny double-stranded RNA sequences coded to destroy genetic material responsible for a virus' protein synthesis, rendering it unable to replicate. The RNA treatment is undergoing preclinical studies, the results from which are expected by the end of the year. Meanwhile, one of the company's antibodies, VIR-7832, will enter phase 2 clinical trials in the fourth quarter, while the other, VIR-7831, is in phase 2/3 clinical trials. The latter candidate could made available first under an early access program like an Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) in the early months of 2021, if trial results are positive.

Vir has partnered with GlaxoSmithKline(NYSE:GSK) to develop its COVID-19 programs. The company is responsible for research and development (R&D) costs while GlaxoSmithKline is handling commercialization costs. Under the agreement, 72.5% of costs and profits go to Vir while the remaining 27.5% are GlaxoSmithKline's.

Without a doubt, Vir's pipeline has potential. However, there are already coronavirus treatments on the market, including Gilead Sciences'(NASDAQ:GILD) antiviral, remdesivir, and the generic steroid, dexamethasone. What's more, large-cap biotechs such as Moderna(NASDAQ:MRNA) andPfizer(NYSE:PFE) are already far along in their efforts to develop coronavirus vaccines. In fact, a vaccine could be available as soon as October. While there are no guarantees that any one of the vaccine candidates in particular will prove effective against COVID-19, it is likely that by 2022, the need for coronavirus treatments will have significantly diminished as people around the world are (hopefully) inoculated.

The company's hepatitis B pipeline is facing similar problems. Even though its treatment candidates for the disease are well into phase 2 trials, the question of their commercial feasibility is a key concern. There are already a number of effective hepatitis B vaccines available worldwide, meaning that the need for a treatment is limited to those who don't get immunized (or those whose immunizations are ineffective) and subsequently contract the virus. While 257 million people are currently living with hepatitis B, many are in developing nations and may not have the purchasing power to afford a pricey treatment course.

If that wasn't enough, Arrowhead Pharmaceuticals (NASDAQ:ARWR) andJohnson & Johnson (NYSE:JNJ) are also on their way to developing a treatment for hepatitis B. Clinical data for their candidate has looked solid. Whatever comes out of Vir's pipeline would have to compete with both existing standard-of-care treatments such as Entecavir and Tenofovir and new ones from other biotechs. This would significantly affect the company's pricing power in the event of its drug's approval.

Vir only brought in $67 million in combined licensing plus collaboration revenues in the past quarter. But currently, it has about $552.4 million in cash and investments, is operating at a net loss of $31.2 million per quarter, and has a $4.05 billion market cap. So in terms of its ability to keep moving forward with research and development, Vir's financial position is fair.

However, I don't think its shaky pipeline can justify its stock price, even after a recent decline. The market opportunities for hepatitis B and COVID-19 treatment candidates are too unstable and full of heavyweight pharma competitors. Buying Vir Biotechnology now could be like catching a falling knife. Investors looking at coronavirus stocks may wish to consider other opportunities.

Link:
Should You Buy Vir Biotechnology Stock on the Dip? - Motley Fool

When I was looking for universities to apply for an undergraduate programme, I heard about Rabindranath Tagore University (RNTU) and decided to visit the campus. I was astonished to see all the facilities offered here. Since the educational institutions in and around Vidisha dont offer similar facilities, I moved to Bhopal to join RNTU for a programme in Biotechnology.

This subject is used in different fields, including agriculture, environment and medicine and is slowly gaining popularity in India, especially in relation to agriculture, organic crops as well as cross breeding.

Infrastructure

At RNTU, we have access to excellent labs and equipment required for research, such as an in-house DNA fingerprinting lab and this makes the educational experience really engrossing.

Also, the teachers are supportive and helpful in creating an interactive learning experience. Presentations and audiovisual lessons and use of technology make the classes compelling.

The exposure to practical learning, as well as extracurricular activities, has improved my management and leadership skills. It has enabled me come out of my shell and explore the world as well as my own capabilities. One of my best experiences was representing my university at a national level debate competition organised by the Amity University, Lucknow.

In addition to participating in competitions, I was also a part of the volunteering committee at Vishwa Rang, the Tagore International Literature and Arts Festival during which I met and interacted with many artists and writers.

I was also a member of the organising team for the annual college festival Rhythm. We decided each act, divided the responsibilities and mapped of various activities with deadlines proper execution.

Even during the lockdown, we are constantly getting various internship opportunities so that our future is not adversely affected by the pandemic.

Kanika Soni is a third-year undergraduate student of Biotechnology from the Rabindranath Tagore University, Bhopal

You have reached your limit for free articles this month.

To get full access, please subscribe.

Already have an account ? Sign in

Show Less Plan

Find mobile-friendly version of articles from the day's newspaper in one easy-to-read list.

Move smoothly between articles as our pages load instantly.

Enjoy reading as many articles as you wish without any limitations.

A one-stop-shop for seeing the latest updates, and managing your preferences.

A select list of articles that match your interests and tastes.

We brief you on the latest and most important developments, three times a day.

*Our Digital Subscription plans do not currently include the e-paper ,crossword, iPhone, iPad mobile applications and print. Our plans enhance your reading experience.

View original post here:
Biotech and beyond - The Hindu

- Corporate restructuring to extend cash runway through mid-2022 and key milestones -

- UBX1325 to enter clinical development in patients with diabetic macular edema -

SAN FRANCISCO, Calif., Sept. 15, 2020 (GLOBE NEWSWIRE) -- UNITY Biotechnology (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to extend healthspan by slowing, halting or reversing diseases of aging, today announced it has initiated a restructuring to align its resources on cellular senescence programs in ophthalmology and neurology while further extending operating capital. UNITY will advance UBX1325 to Phase 1 clinical development in patients with diabetic macular edema, and expects to dose the first patient in the second half of 2020, consistent with prior guidance.

UNITY has prioritized its portfolio and aligned resources to deliver on key development milestones and drive innovation:

UBX1325 targets Bcl-xL, a novel mechanism to eliminate senescent cells in age-related diseases of the eye. The UBX1325 Phase 1 study in diabetic macular edema is expected to begin before the end of the year. UBX1967 remains in the portfolio as a molecularly distinct backup to UBX1325.

UNITYs neurology programs will target core features of neurodegenerative diseases. These programs build upon UNITYs foundational cellular senescence research platform and will focus on senolytic therapies for neurological diseases as well as exploring novel mechanisms for cognitive benefit.

UNITYs research programs will explore therapeutic modalities beyond small molecule approaches to significantly expand the target space for modulating senescent cell biology implicated as drivers of diseases of aging.

Revised Financial Guidance

UNITY will reduce its workforce by approximately 30% to optimize capital allocation and align with key strategic priorities, resulting in an estimated 75 full-time employees by the end of the year. These steps to focus resources are expected to extend the cash runway through mid-2022, with current cash and cash equivalents projected to fund UNITY through key clinical data readouts for UBX1325 and IND-enabling studies for UBX1967.

Story continues

"UNITY is a pioneer in the development of therapeutics targeting senescent cells at the crux of many age-related diseases, and we will continue to build on this scientific foundation as we advance our pipeline," said Anirvan Ghosh, Ph.D., chief executive officer of UNITY. "At UNITY, we have an extraordinary team that has contributed greatly to the advancement of this field, and we are deeply grateful for the contributions that all of our employees have made. Moving forward we will have a leaner and more agile team, which is well-resourced to advance our pipeline programs to key milestones."

Dr. Ghosh added: We are excited about advancing UNITYs lead ophthalmology program, UBX1325, into clinical studies in patients with diabetic macular edema, an indication with a well-defined development path and objective endpoints. In addition, I see significant opportunities emerging from programs in our preclinical pipeline targeting ophthalmologic and neurologic disease. I look forward to using my experience leading drug discovery and development programs in these areas to advance the development of a new class of high efficacy therapies.

About UNITYUNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. More information is available atwww.unitybiotechnology.comor follow us onTwitter.

Forward-Looking Statements

This press release contains forward-looking statements including statements related to UNITYs understanding of cellular senescence and the role it plays in diseases of aging, the potential for UNITY to develop therapeutics to extend healthspan, including for ophthalmologic and neurologic disease, the potential for UNITY to successfully commence and complete clinical studies of UBX1325 for diabetic macular edema and other ophthalmological diseases, the expected timing of initial results of the Phase 1 study of UBX1325 in diabetic macular edema, the expected size of UNITYs workforce following the restructuring, the impact of the workforce reduction on UNITYs business, and UNITYs expectations regarding the sufficiency of its cash runway. These statements involve substantial known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements, including the risk that the COVID-19 worldwide pandemic may continue to negatively impact the development of preclinical and clinical drug candidates, including delaying or disrupting the enrollment of patients in clinical trials. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. The forward-looking statements in this press release represent our views as of the date of this release. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this release. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see UNITYs most recent Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the Securities and Exchange Commission on July 31, 2020, as well as other documents that may be filed by UNITY from time to time with the Securities and Exchange Commission.

Read the original here:
UNITY Biotechnology Announces Actions to Focus on Senolytic Programs in Ophthalmology and Neurology - Yahoo Finance

Latest Research Report: Piceatannol industry

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

Global Piceatannol Market documents a detailed study of different aspects of the Global Market. It shows the steady growth in market in spite of the fluctuations and changing market trends. The report is based on certain important parameters.

Get a Sample PDF copy of the report @ https://reportsinsights.com/sample/148723

Piceatannol Market competition by top manufacturers as follow:Shaanxi Fuheng (FH) BiotechnologyXian Lyphar BiotechXian Finesky TechnologicalXa Bc-BiotechXian Huisun Bio-TechRiotto BotanicalXian Biof Bio-Technology

The risingtechnology in Piceatannolmarketis also depicted in thisresearchreport. Factors that are boosting the growth of the market, and giving a positive push to thrive in the global market is explained in detail. It includes a meticulous analysis of market trends, market shares and revenue growth patterns and the volume and value of the market. It is also based on a meticulously structured methodology. These methods help to analyze markets on the basis of thorough research and analysis.

The Type Coverage in the Market are: Industrial GradePharmaceutical Grade

Market Segment by Applications, covers:DrugsCosmeticsOthers

The research report summarizes companies from different industries. This Piceatannol Market report has been combined with a variety of market segments such as applications, end users and sales. Focus on existing market analysis and future innovation to provide better insight into your business. This study includes sophisticated technology for the market and diverse perspectives of various industry professionals.

Piceatannol is the arena of accounting worried with the summary, analysis and reporting of financial dealings pertaining to a business. This includes the training of financial statements available for public ingesting. The service involves brief, studying, checking and reporting of the financial contacts to tax collection activities and objects. It also involves checking and making financial declarations, scheming accounting systems, emerging finances and accounting advisory.

To get this report at a profitable rate.: https://reportsinsights.com/discount/148723

Market segment by Regions/Countries, this report coversNorth AmericaEuropeChinaRest of Asia PacificCentral & South AmericaMiddle East & Africa

Report Highlights: Detailed overview of parent market Changing market dynamics in the industry In-depth market segmentation Historical, current and projected market size in terms of volume and value Recent industry trends and developments Competitive landscape Strategies of key players and products offered Potential and niche segments, geographical regions exhibiting promising growth A neutral perspective on market performance Must-have information for market players to sustain and enhance their market footprint

Access full Report Description, TOC, Table of Figure, Chart, [emailprotected] https://reportsinsights.com/industry-forecast/Piceatannol-Market-148723

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

:(US) +1-214-272-0234

:(APAC) +91-7972263819

Email:[emailprotected]

Sales:[emailprotected]

Originally posted here:
Piceatannol Market Incredible Possibilities, Growth Analysis and Forecast To 2025 | Shaanxi Fuheng (FH) Biotechnology, Xian Lyphar Biotech, Xian...

Plant Biotechnology Equipment Market Data and Acquisition Research Study with Trends and Opportunities 2019-2025The study of Plant Biotechnology Equipment market is a compilation of the market of Plant Biotechnology Equipment broken down into its entirety on the basis of types, application, trends and opportunities, mergers and acquisitions, drivers and restraints, and a global outreach. The detailed study also offers a board interpretation of the Plant Biotechnology Equipment industry from a variety of data points that are collected through reputable and verified sources. Furthermore, the study sheds a lights on a market interpretations on a global scale which is further distributed through distribution channels, generated incomes sources and a marginalized market space where most trade occurs.

Along with a generalized market study, the report also consists of the risks that are often neglected when it comes to the Plant Biotechnology Equipment industry in a comprehensive manner. The study is also divided in an analytical space where the forecast is predicted through a primary and secondary research methodologies along with an in-house model.

Request a sample of Plant Biotechnology Equipment Market report @ https://hongchunresearch.com/request-a-sample/60575

The following manufacturers are covered:Keygene(Netherlands)Heinz Walz GmbH (Germany)LemnaTec(Germany)Photon Systems Instruments(Czech Republic)Qubit Systems (Canada)Thermo Fisher Scientific (US)Tecan Group (Switzerland)LabRepCo (US)Geneq (Canada)Illumina (US)LGC Limited (UK)Evogene (Israel)

Access this report Plant Biotechnology Equipment Market @ https://hongchunresearch.com/report/worldwide-plant-biotechnology-equipment-market-2019-60575

Segment by RegionsNorth AmericaEuropeChinaJapan

Segment by TypeSensors ModulesImaging DevicesAutomated SystemDronesLED LightingPortable Devices

Segment by ApplicationPlant ResearchBreedingProduct DevelopmentQuality AssessmentOthers

For a global outreach, the Plant Biotechnology Equipment study also classifies the market into a global distribution where key market demographics are established based on the majority of the market share. The following markets that are often considered for establishing a global outreach are North America, Europe, Asia, and the Rest of the World. Depending on the study, the following markets are often interchanged, added, or excluded as certain markets only adhere to certain products and needs.

Here is a short glance at what the study actually encompasses:Study includes strategic developments, latest product launches, regional growth markers and mergers & acquisitionsRevenue, cost price, capacity & utilizations, import/export rates and market shareForecast predictions are generated from analytical data sources and calculated through a series of in-house processes.

However, based on requirements, this report could be customized for specific regions and countries.

To Check Discount of Plant Biotechnology Equipment Market @ https://hongchunresearch.com/check-discount/60575

Major Point of TOC:

Chapter One: Plant Biotechnology Equipment Market Overview

Chapter Two: Global Plant Biotechnology Equipment Market Competition by Manufacturers

Chapter Three: Global Plant Biotechnology Equipment Production Market Share by Regions

Chapter Four: Global Plant Biotechnology Equipment Consumption by Regions

Chapter Five: Global Plant Biotechnology Equipment Production, Revenue, Price Trend by Type

Chapter Six: Global Plant Biotechnology Equipment Market Analysis by Applications

Chapter Seven: Company Profiles and Key Figures in Plant Biotechnology Equipment Business

Chapter Eight: Plant Biotechnology Equipment Manufacturing Cost Analysis

Chapter Nine: Marketing Channel, Distributors and Customers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Plant Biotechnology Equipment Market Forecast

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Methodology and Data Source 13.1 Methodology/Research Approach13.1.1 Research Programs/Design13.1.2 Market Size Estimation13.1.3 Market Breakdown and Data Triangulation13.2 Data Source13.2.1 Secondary Sources13.2.2 Primary Sources13.3 Author List13.4 Disclaimer

About HongChun Research:HongChun Research main aim is to assist our clients in order to give a detailed perspective on the current market trends and build long-lasting connections with our clientele. Our studies are designed to provide solid quantitative facts combined with strategic industrial insights that are acquired from proprietary sources and an in-house model.

Contact Details:Jennifer GrayManager Global Sales+ 852 8170 0792[emailprotected]

Link:
Impact Of Covid-19 on Plant Biotechnology Equipment Market 2020 Industry Challenges, Business Overview and Forecast Research Study 2026 - The Daily...

Executive summary:

The latest report on Biotechnology Separation Systems market strives to provide a conclusive overview of the current and future market scenario with respect to the key growth catalysts, challenges, and opportunities across the various geographies.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

The Biotechnology Separation Systems market is projected to expand with a CAGR of XX% during the forecast period 2020-2025.

Request Sample Copy of this Report @ https://www.theresearchprocess.com/request-sample/6449

In addition to region wise-assessment, the study also draws attention towards the competitive landscape by profiling the top contenders in the industry. A complete analysis of the various market segmentation is underlined in the report. Additionally, a detailed visualization of the global Covid-19 impact on the growth matrix of this business space is provided.

Market synopsis:

Regional outlook:

Product terrain outline:

Application spectrum overview:

Competitive landscape review:

Additional information from the Biotechnology Separation Systems market report:

Development policies and plans are discussed as well as manufacturing processes and cost structures are also analyzed. This report also states import/export consumption, supply and demand Figures, cost, price, revenue and gross margins.

Market segmentation

The Biotechnology Separation Systems market is split by Type and by Application. For the period 2020-2025, the growth among segments provides accurate calculations and forecasts for sales by Type and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.

Research Objective:

Why to Select This Report:

The research process begins with internal and external sources to obtain qualitative and quantitative information related to the Biotechnology Separation Systems market. It also provides an overview and forecast for the Biotechnology Separation Systems market based on all the segmentation provided for the global region. The predictions highlighted in the Biotechnology Separation Systems market share report have been derived using verified research procedures and assumptions. By doing so, the research report serves as a repository of analysis and information for every component of the Biotechnology Separation Systems market.

Request Customization on This Report @ https://www.theresearchprocess.com/request-for-customization/6449

Read the rest here:
Biotechnology Separation Systems Market Analysis, Revenue, Share, Growth Rate & Forecast To 2025 - The Research Process

REHOVOT, Israel and SILVER SPRING, Maryland, Sept. 21, 2020 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN) and United Therapeutics Corporation (NASDAQ: UTHR) today announced an expansion of their collaboration with the exercise by United Therapeutics of its option to cover a second lifesaving organ, human kidneys. United Therapeutics paid CollPlant $3 million for the option exercise.

The collaboration agreement combines CollPlant's proprietary recombinant human collagen (rhCollagen) and BioInk technology with the regenerative medicine and organ manufacturing capabilities of United Therapeutics.

The option exercise grants United Therapeutics through its wholly owned organ manufacturing and transplantation-focused subsidiary, Lung Biotechnology PBC, an exclusive license to CollPlant's technology for the production and use of rhCollagen-based BioInk for 3D bioprinting of human kidneys. This expanded collaboration is aimed at helping reduce global organ shortages and thereby potentially saving lives of millions of patients on kidney waiting lists.

"Organ shortages are an unmet global health need and by partnering with United Therapeutics for the past couple of years, we have made significant progress with this pivotal organ manufacturing initiative," stated Yehiel Tal, the Chief Executive Officer of CollPlant. "United Therapeutics is pioneering the emerging organ manufacturing field, and we are honored to be part of this effort via this partnership. This option exercise demonstrates another important validation of our rhCollagen platform technology, performing as an optimal building block for regenerative medicine. We remain committed to exploring new innovative applications in the fields of medical aesthetics and 3D bioprinting of tissues and organs."

"We are excited to expand our collaboration with CollPlant's extraordinary technology to transform the tobacco plant one that is so associated with devastating diseases into a collagen-expressing plant that will be essential to the production of an unlimited number of transplantable organs," said Martine Rothblatt, Ph.D., Chairman and Chief Executive Officer of United Therapeutics. "Our collagen-expressing plants are already flourishing in Texas where we enjoy three growing seasons."

The collaboration agreement itself, which was signed in October 2018, granted United Therapeutics an exclusive license to CollPlant's technology for the production and use of rhCollagen-based BioInk for 3D bioprinted lung transplants. CollPlant will manufacture and supply BioInk for a few years to meet development process demand and will provide technical support to United Therapeutics as it establishes a U.S. facility for the manufacture of CollPlant's rhCollagen and BioInk.

Under financial terms of the original collaboration agreement, CollPlant received an upfront payment of $5 million and will receive milestone payments of up to $15 million based on the achievement of certain operational and regulatory milestones related to the development of manufactured lungs. The agreement also provides United Therapeutics with an option to extend the license to two remaining additional life-saving organs with option exercise payments of up to $6 million. As a result of the option exercise for human kidneys these options have been extended for an additional one year through November 9, 2021. The agreement also provides additional developmental milestone payments of up to $15 million if United Therapeutics elects to develop manufactured organs other than lungs using CollPlant's technology. CollPlant will also be entitled to royalties on sales of commercialized products covered by patents licensed from CollPlant.

About CollPlant

CollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. CollPlant's products are based on its rhCollagen (recombinant human collagen) that is produced with CollPlant's proprietary plant based genetic engineering technology.

CollPlant's products address indications for the diverse fields of tissue repair, aesthetics and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine.

CollPlant's flagship rhCollagen BioInk product line is ideal for 3D bioprinting of tissues and organs. In October 2018, CollPlant entered into a licensing agreement with United Therapeutics, whereby United Therapeutics is using CollPlant's BioInks in the manufacture of 3D bioprinted lungs for transplant in humans.

In January 2020, CollPlant entered into a Joint Development Agreement with 3D Systems Corporation, or 3D Systems, pursuant to which CollPlant and 3D Systems jointly develop tissue and scaffold bioprinting processes for third party collaborators. CollPlant's industry collaboration also includes the Advanced Regenerative Manufacturing Institute, or ARMI.

For more information, visit http://www.collplant.com.

About United Therapeutics Corporation

United Therapeutics Corporation focuses on the strength of a balanced, value-creating biotechnology model. We are confident in our future thanks to our fundamental attributes, namely our obsession with quality and innovation, the power of our brands, our entrepreneurial culture, and our bioinformatics leadership. We also believe that our determination to be responsible citizens having a positive impact on patients, the environment, and society will sustain our success in the long term.

Through our wholly owned subsidiary, Lung Biotechnology PBC, we are focused on addressing the acute national shortage of transplantable lungs and other organs with a variety of technologies that either delay the need for such organs or expand the supply. Lung Biotechnology is the first public benefit corporation subsidiary of a public biotechnology or pharmaceutical company.

Safe Harbor for Forward-Looking Statements

This press release may include forward-looking statements. Forward-looking statements may include, but are not limited to, statements relating to CollPlant's and United Therapeutics' objectives, plans and strategies, as well as statements, other than historical facts, that address activities, events or developments that CollPlant and United Therapeutics each intends, expects, projects, believes or anticipates will or may occur in the future. These statements are often characterized by terminology such as "believes," "hopes," "may," "anticipates," "should," "intends," "plans," "will," "expects," "estimates," "projects," "positioned," "strategy" and similar expressions and are based on assumptions and assessments made in light of management's experience and perception of historical trends, current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. Many factors could cause CollPlant's and United Therapeutics' actual activities or results to differ materially from the activities and results anticipated in forward-looking statements, including, but not limited to, the following: the CollPlant's history of significant losses and its need to raise additional capital and its inability to obtain additional capital on acceptable terms, or at all; CollPlant's and United Therapeutics' expectations regarding the timing and cost of commencing clinical trials with respect to tissues and organs which are based on its rhCollagen-based BioInk; the CollPlant's and United Therapeutics' ability to obtain favorable pre-clinical and clinical trial results; regulatory action with respect to rhCollagen-based BioInk, including but not limited to acceptance of an application for marketing authorization, review and approval of such application, and, if approved, the scope of the approved indication and labeling; commercial success and market acceptance of the CollPlant's rhCollagen-based BioInk and United Therapeutics' manufactured organs; CollPlant's ability to establish sales and marketing capabilities or enter into agreements with third parties and its reliance on third-party distributors and resellers; CollPlant's and United Therapeutics' ability to establish and maintain strategic partnerships and other corporate collaborations; CollPlant's and United Therapeutics' reliance on third parties to conduct some aspects of its product manufacturing; the scope of protection CollPlant and United Therapeutics are able to establish and maintain for intellectual property rights and the companies' ability to operate their business without infringing the intellectual property rights of others; the overall global economic environment; the impact of competition and new technologies; general market, political, and economic conditions in the countries in which the companies operate; projected capital expenditures and liquidity; changes in the companies' strategy; and litigation and regulatory proceedings. More detailed information about the risks and uncertainties affecting CollPlant and United Therapeutics is contained under the heading "Risk Factors" included in CollPlant's and United Therapeutics' most recent annual report on Form 20-F and Form 10-K, respectively, filed with the SEC, and in other filings that CollPlant and United Therapeutics have made and may make with the SEC in the future. The forward-looking statements contained in this press release are made as of the date of this press release and reflect CollPlant's and United Therapeutics' current views with respect to future events, and neither company undertakes, and each company specifically disclaims, any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Contacts at CollPlant:Eran RotemDeputy CEO & Chief Financial OfficerTel: + 972-73-2325600/612Email: Eran@collplant.com

Sophia Ononye-Onyia, PhD MPH MBAFounder & CEO, The Sophia Consulting FirmTel: +1-347-851-8641E-mail: sophia@sophiaconsultingfirm.com

Contact at United Therapeutics:Dewey SteadmanHead of Investor RelationsTel: + 1 (202) 919-4097Email: ir@unither.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/collplant-and-united-therapeutics-announce-exercise-of-option-that-will-expand-their-collaboration-to-include-3d-bioprinting-of-human-kidneys-for-transplant-301134527.html

SOURCE CollPlant; United Therapeutics Corporation

Company Codes: NASDAQ-NMS:CLGN, ISIN:IL0004960188, RICS:CLPT.TA, RICS:CQPTY, NASDAQ-NMS:UTHR

The rest is here:
CollPlant and United Therapeutics Announce Exercise of Option that will Expand their Collaboration to Include 3D Bioprinting of Human Kidneys for...

PDS Biotechnology Corporation [NASDAQ: PDSB] price surged by 10.98 percent to reach at $0.28. The company report on September 8, 2020 that PDS Biotechnology to Participate in Upcoming Healthcare Investor Conferences.

PDS Biotechnology Corporation (PDS Biotech or the Company) (Nasdaq: PDSB), a clinical-stage immunotherapy company developing novel cancer therapies and infectious disease vaccines based on the Companys proprietary Versamune T-cell activating technology, today announced that Frank Bedu-Addo, CEO of PDS Biotech, will present virtually at the H.C. Wainwright & Co. 22nd Annual Global Investment Conference on September 16th and the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on September 23rd.

H.C. Wainwright & Co. 22nd Annual Global Investment Conference:Date: Wednesday, September 16th, 2020Location: https://wsw.com/webcast/hcw7/pdsb/1599649Time: 2:30 PM ET.

A sum of 1192998 shares traded at recent session while its average daily volume was at 1.90M shares. PDS Biotechnology Corporation shares reached a high of $2.85 and dropped to a low of $2.45 until finishing in the latest session at $2.83.

The average equity rating for PDSB stock is currently 2.20, trading closer to a bullish pattern in the stock market.

Alliance Global Partners have made an estimate for PDS Biotechnology Corporation shares, keeping their opinion on the stock as Buy, with their previous recommendation back on May 27, 2020. While these analysts kept the previous recommendation, Noble Capital Markets raised their target price to Outperform. The new note on the price target was released on March 09, 2020, representing the official price target for PDS Biotechnology Corporation stock. Previously, the target price had yet another raise to $10, while Chardan Capital Markets analysts kept a Buy rating on PDSB stock.

The Average True Range (ATR) for PDS Biotechnology Corporation is set at 0.22 The Price to Book ratio for the last quarter was 2.55, with the Price to Cash per share for the same quarter was set at 0.88.

PDS Biotechnology Corporation [PDSB] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 31.02. With this latest performance, PDSB shares dropped by -4.07% in over the last four-week period, additionally plugging by 322.39% over the last 6 months not to mention a drop of -50.44% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for PDSB stock in for the last two-week period is set at 55.48, with the RSI for the last a single of trading hit 67.29, and the three-weeks RSI is set at 53.92 for PDS Biotechnology Corporation [PDSB]. The present Moving Average for the last 50 days of trading for this stock 2.98, while it was recorded at 2.55 for the last single week of trading, and 1.93 for the last 200 days.

Return on Total Capital for PDSB is now -74.68, given the latest momentum, and Return on Invested Capital for the company is -33.70. Return on Equity for this stock declined to -33.70, with Return on Assets sitting at -27.60.

Reflecting on the efficiency of the workforce at the company, PDS Biotechnology Corporation [PDSB] managed to generate an average of -$349,930 per employee.PDS Biotechnology Corporations liquidity data is similarly interesting compelling, with a Quick Ratio of 7.70 and a Current Ratio set at 7.70.

With the latest financial reports released by the company, PDS Biotechnology Corporation posted -1.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.82/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -34.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for PDSB.

There are presently around $5 million, or 8.00% of PDSB stock, in the hands of institutional investors. The top three institutional holders of PDSB stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 622,672, which is approximately 101.108% of the companys market cap and around 35.92% of the total institutional ownership; FEDERATED HERMES, INC., holding 384,000 shares of the stock with an approximate value of $1.09 million in PDSB stocks shares; and FIRST MANHATTAN CO, currently with $0.42 million in PDSB stock with ownership of nearly 0% of the companys market capitalization.

Positions in PDS Biotechnology Corporation stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 10 institutional holders increased their position in PDS Biotechnology Corporation [NASDAQ:PDSB] by around 462,139 shares. Additionally, 12 investors decreased positions by around 392,147 shares, while 14 investors held positions by with 848,804 shares. The mentioned changes placed institutional holdings at 1,703,090 shares, according to the latest SEC report filing. PDSB stock had 6 new institutional investments in for a total of 72,701 shares, while 9 institutional investors sold positions of 372,040 shares during the same period.

Follow this link:
PDS Biotechnology Corporation [PDSB] gain 6.79% so far this year. What now? - The DBT News

The 94 rating InvestorsObserver gives to Aquestive Therapeutics Inc (AQST) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 100 percent of stocks in the Biotechnology industry, AQSTs 94 overall rating means the stock scores better than 94 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 94 would rank higher than 94 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Aquestive Therapeutics Inc (AQST) stock is trading at $8.78 as of 3:10 PM on Monday, Sep 21, a decline of -$0.27, or -2.98% from the previous closing price of $9.05. The stock has traded between $8.52 and $9.09 so far today. Volume today is 945,661 compared to average volume of 1,159,181.

Click Here to get the full Stock Score Report on Aquestive Therapeutics Inc (AQST) Stock.

View original post here:
Is Aquestive Therapeutics Inc (AQST) the Top Pick in the Biotechnology Industry? - InvestorsObserver

MacroGenics Inc (MGNX) is near the top in its industry group according to InvestorsObserver. MGNX gets an overall rating of 64. That means it scores higher than 64 percent of stocks. MacroGenics Inc gets a 75 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

MacroGenics Inc (MGNX) stock is trading at $27.70 as of 1:10 PM on Monday, Sep 21, a decline of -$3.90, or -12.34% from the previous closing price of $31.60. The stock has traded between $27.45 and $30.56 so far today. Volume today is 456,042 compared to average volume of 558,970.

Click Here to get the full Stock Score Report on MacroGenics Inc (MGNX) Stock.

Originally posted here:
Is MacroGenics Inc (MGNX) a Winner in the Biotechnology Industry? - InvestorsObserver

Debut Bio

SAN DIEGO (PRWEB) September 15, 2020

Debut Biotechnology, a UC-Irvine spinout advancing scalable cell-free biomanufacturing, today announced that it has been awarded $1M from the Air Force Research Labs Biotechnology Grand Challenge. Debut Bio is the inaugural recipient of the award, which honors the companys proposal on biosynthesis of monomers for aerospace applications.

In the proposal, Debut Bio details its ability to leverage the companys scalable biomanufacturing platform for bio- and metal-free synthesis of polymer precursors relevant for the aerospace industry. Debut Bios platform will provide AFRL with the ability to effectively and efficiently biomanufacture specialty ingredients needed for aerospace applications. In doing so, Debut Bio expects to reduce aerospace material costs and improve vehicle maintenance processes by extending service lifetimes.

The Air Force Research Lab has a well-documented history in discovering and leveraging breakthrough technologies. By offering a cell-free, continuous biomanufacturing process, we are excited to continue that legacy of innovation through our work with them, said Dr. Joshua Britton, CEO and Founder of Debut Biotechnology. Cell-free biomanufacturing enables the quality manufacturing of high-value molecules at a price point that scales far beyond what is possible today. In bringing this approach to the AFRL, we hope to usher in a new era of biomanufacturing for high-value molecules that is scalable, economically viable, and results in solutions that are efficient and effective.

Debut Bio has applied its technology to the pharmaceutical and specialty ingredient industries, allowing customers to manufacture high-value molecules by combining custom-designed immobilized enzymes with continuous biomanufacturing processes. Through the utilization of plug-and-play enzyme cartridges, the companys cell-free platform has the ability to transform low-value bio-renewable materials into high-value specialty chemicals.

The Debut Biotechnology proposal provides a path to a scalable, bio- and metal free synthesis of key aerospace polymer precursors, explained Dr. Davide Simone, AFRLs technology advisor for biosynthesis of monomers for aerospace thermosets and senior research chemist. Expected benefits for the Air Force include a significant savings in composite aerospace structural material costs and the elimination of oxidation promoting metal catalysts from structural components, extending service lifetimes.

Debut Bios enzyme cartridges are sequentially arranged in a manner which mimics pathways found in plants and other organisms. Each cartridge is finely-tuned to provide the ideal temperature, pH, concentration, solvent, and reaction time for each individual step to maximize enzymatic productivity and product titer levels. The platform requires far fewer steps than traditional materials manufacturing and avoids the use of environmentally harmful chemical synthesis. Importantly, it overcomes many challenges typically associated with relying on cells for biomanufacturing or extraction of ingredients from plants and other sources.

In Debut Bios system, materials are passed from one enzyme reactor to another to build in-vitro or cell-free biosynthetic pathways. The companys platform uses a sustainable approach by leveraging advanced enzymes outside of the cell to maximize performance and avoid issues with cell-based fermentation systems. The platform technology operates under a continuous manufacturing regime, allowing Debut Bio to scale beyond the capabilities of other manufacturing processes currently on the market, which are constrained by the precipitation of enzymes, the need for multiple large reactors, and the specific requirements of enzymes. By leveraging continuous manufacturing, Debut Bio is able to drive down the cost of cell-free manufacturing to provide scale, consistency, novelty, and ultimately the ability to produce a biomolecule with the click of a button.

Debut Bio serves organizations across the defense and specialty ingredient industries, with commitments from several large scale manufacturers to integrate its platform into their existing pipelines.

To learn more, please visit: https://debutbiotech.com.

About Debut Biotechnology

Debut Biotechnology is commercializing cell-free biomanufacturing solutions by creating advanced enzyme-based manufacturing processes for high-value molecules. Our platform combines immobilized enzymes with highly controlled and automated continuous manufacturing systems for the pharmaceutical and specialty chemical industries.

Debut Biotechnology was founded by Joshua Britton, Greg Weiss, and Brady Beauchamp and is based in sunny San Diego. To learn more, please visit: https://debutbiotech.com/.

Share article on social media or email:

Continued here:
Debut Biotechnology Awarded $1M from Air Force Research Lab to Leverage Cell-Free Continuous Biomanufacturing in Aerospace Applications - PR Web

Nantkwest Inc (NK) is around the top of the Biotechnology industry according to InvestorsObserver. NK received an overall rating of 62, which means that it scores higher than 62 percent of all stocks. Nantkwest Inc also achieved a score of 79 in the Biotechnology industry, putting it above 79 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Analyzing stocks can be hard. There are tons of numbers and ratios, and it can be hard to remember what they all mean and what counts as good for a given value. InvestorsObserver ranks stocks on eight different metrics. We percentile rank most of our scores to make it easy for investors to understand. A score of 62 means the stock is more attractive than 62 percent of stocks.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Nantkwest Inc (NK) stock is trading at $7.94 as of 1:12 PM on Monday, Sep 14, a gain of $1.34, or 20.3% from the previous closing price of $6.60. The stock has traded between $6.84 and $7.97 so far today. Volume today is above average. So far 1,740,191 shares have traded compared to average volume of 1,370,495 shares.

Click Here to get the full Stock Score Report on Nantkwest Inc (NK) Stock.

Read the original post:
Where Does Nantkwest Inc (NK) Stock Fall in the Biotechnology Field? - InvestorsObserver

Evelo Biosciences Inc (EVLO) is around the middle of the Biotechnology industry according to InvestorsObserver. EVLO received an overall rating of 44, which means that it scores higher than 44 percent of all stocks. Evelo Biosciences Inc also achieved a score of 45 in the Biotechnology industry, putting it above 45 percent of Biotechnology stocks. Biotechnology is ranked 31 out of the 148 industries.

Finding the best stocks can be tricky. It isnt easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObservers tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObservers overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. Theres no need to try to remember what is good for a bunch of complicated ratios, just pay attention to which numbers are the highest.

Evelo Biosciences Inc (EVLO) stock is trading at $5.08 as of 2:35 PM on Monday, Sep 14, a rise of $0.39, or 8.32% from the previous closing price of $4.69. The stock has traded between $4.81 and $5.22 so far today. Volume today is less active than usual. So far 65,585 shares have traded compared to average volume of 145,817 shares.

Click Here to get the full Stock Score Report on Evelo Biosciences Inc (EVLO) Stock.

Originally posted here:
Is Evelo Biosciences Inc (EVLO) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 70 rating InvestorsObserver gives to Avid Bioservices Inc (CDMO) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 90 percent of stocks in the Biotechnology industry, CDMOs 70 overall rating means the stock scores better than 70 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 70 would rank higher than 70 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Avid Bioservices Inc (CDMO) stock is trading at $7.69 as of 10:59 AM on Monday, Sep 14, a gain of $0.51, or 7.03% from the previous closing price of $7.18. The stock has traded between $7.27 and $7.78 so far today. Volume today is 347,046 compared to average volume of 413,400.

Click Here to get the full Stock Score Report on Avid Bioservices Inc (CDMO) Stock.

Here is the original post:
Where Does Avid Bioservices Inc (CDMO) Stock Fall in the Biotechnology Field? - InvestorsObserver

Kolkata, Sep 14 (UNI) GlaxoSmithKline Pharmaceuticals Ltd. (GSK Pharmaceutical Ltd.) in collaboration with the Regional Centre for Biotechnology (RCB) has completed the first year of its Trust in Science Program and is marking it by hosting a six part Trust in Science webinar series. The first webinar was held today. Like the program, these webinars are also an academia-industry collaboration in which experts from the private sector and scientific community will provide insights on trends in bioinformatics and biostatistics and the future outlook of this valuable skill set. The Trust in Science program offers full PhD courses in Biostatistics and Bioinformatics to equip Indian students for a career in a data and AI-driven pharma research ecosystem.

Commenting on the progress of the program, Prof. Sudhanshu Vrati, Executive Director, Regional Centre for Biotechnology, said, Biostatistics and bioinformatics are rapidly emerging fields in biology and are set to change the way we approach scientific R&D. In the first year of this program, we got a good response from aspiring PhD candidates eager to explore scientific careers in these fields. Now, through our webinar series, we hope to reach out to even more Indian students and faculty to make them aware of the potential that lies in these fields and to realize the value of the Trust in Science PhD program.

In the keynote address, HE Jan Thompson, Acting British High Commissioner to India, said the Trust in Science initiative is a great example of public-private-partnership. She added, It is my hope that the Trust in Science initiative will give young researchers an opportunity to explore high-end expertise in drug discovery and the program becomes a spring-board for them to transition into a full-fledged pharma career in the future. The UK and Indian governments continue to work together in healthcare, exploring opportunities for some of the best UK companies to offer their products and services for improved healthcare delivery in India.

Dr. Renu Swarup, Secretary, Department of Biotechnology, Government of India, said, It is great to see that this RCB-GSK collaboration is more than a research budget collaboration between academia and industry, but one that looks to create a human resource foundation for new technology. I would like to see this partnership scaled up, with more partners included so that it becomes a national network for the country. I believe this webinar series can reach out to more people and draw in more institutes to see the value of this partnership..

Mr. Sridhar Venkatesh, Managing Director, GSK Pharmaceuticals Limited (India) said, The ongoing pandemic has highlighted the value of biostatistics and bioinformatics tools and methodologies to significantly reduce the time taken for a medicine to be brought from lab to market. This is the future of pharmaceuticals research and we believe that the Trust in Science programme is contributing to prepare a workforce that is future ready. We hope the webinar series will help aspiring PhD students to get a primer on the likely future of pharma research.

The launch webinar concluded with a learning session by Prof Partha Mazumdar, distinguished Professor, National Institute of Biomedical Genomics, who said, A confluence of statistical science and data science is the enabler of rapid and robust inferences in biology and medicine. He also spoke of the critical value of biostatistics and bioinformatics during the ongoing pandemic by referring to the study on the diversity and evolution of the coronavirus SARS-CoV-2 through the analysis of RNA sequences collected from 3636 infected patients across 55 countries. This is an exciting time in modern biology and medicine, he added, referring to the coming together of statics and big data analysis.

GSK Pharmaceutical Ltd.s Trust in Science initiative is a novel public-private partnership model to build R&D capacity for development and discovery in science. The pillars of this initiative are: scientific excellence, trust and talent development in line with GSKs Science, Technology and Culture values. The initiative was launched in 2011 initially to engage with leading researchers and institutions in Latin America, focused on Brazil and Argentina. GSK Pharmaceutical Ltd. is pleased to expand this initiative beyond Latin America to other emerging markets such as India.UNI SJC AND

Original post:
GSK Pharmaceuticals (India) in collaboration with Regional Centre for Biotechnology completes one year of 'Trust in Science' academia-industry...

A rating of 77 puts ChemoCentryx Inc (CCXI) near the top of the Biotechnology industry according to InvestorsObserver. ChemoCentryx Inc's score of 77 means it scores higher than 77% of stocks in the industry. ChemoCentryx Inc also received an overall rating of 60, putting it above 60% of all stocks. Biotechnology is ranked 31 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 60 would rank higher than 60 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

ChemoCentryx Inc (CCXI) stock is trading at $53.41 as of 2:38 PM on Monday, Sep 14, an increase of $5.34, or 11.11% from the previous closing price of $48.07. The stock has traded between $48.54 and $53.69 so far today. Volume today is light. So far 346,181 shares have traded compared to average volume of 475,545 shares.

Click Here to get the full Stock Score Report on ChemoCentryx Inc (CCXI) Stock.

Read the original post:
Is ChemoCentryx Inc (CCXI) The Right Choice in Biotechnology? - InvestorsObserver